Little is known about the impact of combustion-free nicotine delivery sistem on T2DM patients who smoke. DIASMOKE (Assenssing the impact of combustion free-nicotine delivery technologies in Diabetic Smokers) is an internation, multicentre, open label randomized controlled study designed to determine wheter T2DM cigarette smokers switching to CF-NDS experience measurable improvement in cardiovascular risk parameters as a consequence of avoiding exposure to cigarette smoke toxicants.
This study aims to test the hypothesis that avoiding exposure to cigarette smoke toxicants may translate to measurable improvement in cardiovascular risk factors and functional parameters when type 2 diabetes mellitus (T2DM) patients who smoke switch to using C-F NDS compared with T2DM patients who continue to smoke conventional tobacco products.
Your health will be monitored and monitored continuously.
Diasmoke is a Project by CoEHAR Center of Excellence for the Accelleration of Harm Reduction of the University of Catania, founded by Prof. Riccardo Polosa of Excellence